Unigene Laboratories Inc., of Boonton, N.J., will sell its 45 percent equity interest in Chinese joint venture Unigene Biotechnology Co. Ltd. to China Pharmaceutical Group Ltd., of Hong Kong, or one of its affiliates, for $1.05 million. China Pharmaceutical Group and its affiliates are subsidiaries of Shijiazhuang Pharmaceutical Group Corp. Unigene said that all technology licenses, sublicenses and other rights granted to the joint venture and China Pharmaceutical Group have been returned to Unigene.